Perspectives

The IRA provides Medicare with the opportunity to negotiate drug prices. While there is preliminary direction about how maximum fair price will be calculated, speculation exists regarding how the negotiation process will work, evolve over time, and impact other areas of drug innovation and physician reimbursement. There is also the potential for other less obvious unintended market consequences that may change patient access to care, physician reimbursement, and pricing in other payer/purchaser segments beyond Medicare. Learn more in our recent article.

In part two of our series, ‘Opportunities for Enhanced Communication between Manufacturers and US Payers’, our experts explore Pre-Approval Information Exchange (PIE), including what it is, how and when to communicate PIE, and why having a PIE strategy is essential to the success of both payers and pharmaceutical manufacturers.

Digital technologies are becoming more prevalent across the healthcare field, and new applications in oncology have begun to emerge. These applications span a wide range, operating at the level of populations or for individuals, and for a wide variety of stakeholders.

Learn more about how burden of illness (BoI) studies alongside PRO data in HTA submissions can help decision-makers to make more informed decisions.